Ozempic Stopped & Heart Risk Rebounds

Podcast: The Health Marketing Daily · Marco & Klara

Opublikowano: 2026-09-24

Stopping Ozempic rebounds heart risk — and that's a direct opening for supplement brands. Plus AB InBev is moving into functional beverages, and when the world's largest brewer shifts, shelf space shifts with it. In this episode: A large new study finds cardiovascular risk — including heart attack and stroke — rebounds surprisingly quickly after patients stop GLP-1 drugs like Ozempic and Wegovy, strengthening the commercial case for supplement brands positioned around metabolic continuity and heart health. Impossible Foods has entered UK retail grocery for the first time with product formats developed specifically for British consumers, making a high-stakes bet th...